title: Antiretroviral treatment update from the 17th International AIDS Conference.
authors.affiliation: ViralEd LLC, Stockton, NJ, USA.
authors.forename: Brian
authors.initials: B
authors.lastname: Boyle
authors.forename: Cal
authors.initials: C
authors.lastname: Cohen
authors.forename: Edwin
authors.initials: E
authors.lastname: DeJesus
authors.forename: Richard
authors.initials: R
authors.lastname: Elion
authors.forename: Ian
authors.initials: I
authors.lastname: Frank
authors.forename: Graeme
authors.initials: G
authors.lastname: Moyle
authors.forename: Paul
authors.initials: P
authors.lastname: Sax
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000517:prevention & control*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D000077592:Maraviroc; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000068898:Raltegravir Potassium; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D019428:HIV Integrase Inhibitors; D011760:Pyrrolidinones; D018894:Reverse Transcriptase Inhibitors; D014230:Triazoles; D000068898:Raltegravir Potassium; D000077592:Maraviroc